Cleveland Clinic Taussig Cancer Institute presents
From MDS to AML
and Back Again:
How Disease Biology Allows Us
to Personalize Therapy
Friday, December 4, 2009
Sheraton New Orleans Hotel,
Grand Ballroom C
New Orleans, LA
This is a Satellite Symposium organized by the Cleveland Clinic Myelodysplastic Syndromes Program, preceding the 51st ASH Annual Meeting.
Registration for this event is complimentary.
Description
The bone marrow failure syndromes, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), affect hundreds of thousands of people worldwide. The epidemiology, risk factors, and molecular characterization of these diseases vary in different countries. AML is the most common leukemia in the world, with the highest incidence rates in the United States, Australia, and western Europe. Incidence rates for MDS range from 1 per 100,000 in Japan to 12 per 100,000 in the United Kingdom; the US rate is 3.4 per 100,000. The scientific understanding of the molecular pathogenesis of these disorders has exploded in the past decade, and with it has come advances in pathobiologically driven therapies and predictors of response to therapies, the availability of which also varies across the world.
The goal of this program is to educate international hematology practitioners and researchers on the distribution and subtypes of MDS and AML worldwide.
In addition to pathobiology and clonal evolution, it will also explore disease progression and treatment approaches for patients with MDS or AML syndromes with a focus on overlapping therapies. Participants will be empowered to develop treatment strategies that target mechanisms of neoplastic evolution and other basic MDS and AML disorder mechanisms.
Target Audience
The satellite symposium is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied healthcare professionals treating patients with MDS or AML. In addition, members of patient advocacy groups will benefit from this program.
Objectives
After completing this learning activity, the participant will be able to do the following:
- Summarize the underlying pathogenesis of MDS and AML and assess its impact on clinical practice;
- Describe the mechanisms of transformation of MDS to AML;
- Compare and contrast the treatment goals for MDS and AML and how they overlap;
- Evaluate the clinical implications of using MDS therapies in AML patients and vice-versa;
- Design a management strategy for improving outcomes in patients with MDS or AML.
Faculty
| Steven D. Gore, MD Professor of Oncology Sidney Kimmel Comprehensive Cancer Care Center at Johns Hopkins Hospital Baltimore, Maryland |
Luca Malcovati, MD Assistant Professor of Hematology Department of Hematology University of Pavia Medical School Pavia, Italy |
| Alice Houk, MS Director, Health Professional Programs Aplastic Anemia & Myelodysplastic Syndromes International Foundation, Inc., Rockville, Maryland |
Richard M. Stone, MD Director, Leukemia Program Dana-Farber Cancer Institute Professor of Medicine Harvard Medical school Boston, Massachusetts |
| Jaroslaw P. Maciejewski, MD, PhD Chairman and Professor of Medicine Department of Translational Hematology & Oncology Research Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio |
Richard A. Wells MD, DPhil, FRCPC Director, Cancer Research Odette Cancer Centre Sunnybrook Health Sciences Centre Toronto, Canada |
Agenda
| FRIDAY, DECEMBER 4, 2009 | |
| 6:00 pm | Registration and Reception |
| 6:50 pm | Introduction - Jaroslaw Maciejewski, MD, PhD |
| 7:00 pm | The Changing Clinical Picture of MDS and AML Worldwide - Luca Malcovati, MD |
| 7:25 pm | MDS Progression to AML: Mechanisms of Clonal Evolution - Jaroslaw Maciejewski, MD, PhD |
| 7:50 pm | MDS and AML Therapeutic Strategies: Similarities, Differences, and Overlap - Steven Gore, MD |
| 8:15 pm | Clinical Implications: Applying MDS Therapies to AML Patients and Vice-Versa - Richard Stone, MD |
| 8:40 pm | Effective Management Strategies for Improving Outcomes in MDS or AML Patients - Richard Wells, MD |
| 9:05 pm | Future Directions in Pharmacotherapy: Outcomes for MDS and AML Patients - Alice Houk, MS |
| 9:20 pm | Discussion |
| 9:50 pm | Adjourn |
A five-minute question and answer period
is included in each presentation. |
|
Location
Sheraton New Orleans Hotel |
Additional Information
For further information about this symposium, contact UNITECH Communications® at:
Local: 216-448-0770
Toll Free: 800-238-6750
Fax: 216-448-0783
For questions about registering online, call 216-448-0777 or email CMEregistration@ccf.org.
Faculty Disclosure
The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.
Americans with Disabilities Act
The Cleveland Clinic Foundation Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify UNITECH Communications® at 216-448-0770 or 800-238-6750 at least two weeks prior to the activity.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Registration and Cancellation
Pre-registrations are accepted by fax or online until 5:00 pm ET December 1, 2009. To register after this date, please do so on-site.
Online Registration/Fees
| Category | Full Course |
|---|---|
| All Attendees | complimentary |
